Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Diana Ayan

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Bioorganic & Medicinal Chemistry Letters|July 26, 2011
Synthesis and preliminary evaluation of a modified estradiol-core bearing a fused γ-lactone as non-estrogenic inhibitor of 17β-hydroxysteroid dehydrogenase type 1Etienne Ouellet, Diana Ayan, Donald Poirier
Chemmedchem|June 8, 2012
Identification of a 17β-hydroxysteroid dehydrogenase type 10 steroidal inhibitor: a tool to investigate the role of type 10 in Alzheimer's disease and prostate cancerDiana Ayan, René Maltais, Donald Poirier
ACS Medicinal Chemistry Letters|September 20, 2011
Crucial Role of 3-Bromoethyl in Removing the Estrogenic Activity of 17β-HSD1 Inhibitor 16β-(m-Carbamoylbenzyl)estradiolRené Maltais, Diana Ayan, Donald Poirier
The Journal of Steroid Biochemistry and Molecular Biology|August 11, 2011
Impact of estradiol structural modifications (18-methyl and/or 17-hydroxy inversion of configuration) on the in vitro and in vivo estrogenic activityDiana Ayan, Jenny Roy, René Maltais, et al.
Journal of Medicinal Chemistry|May 8, 2019
Antisulfatase, Osteogenic, and Anticancer Activities of Steroid Sulfatase Inhibitor EO-33 in MiceDonald Poirier, Jenny Roy, René Maltais, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|April 30, 2026
Code Stroke Activation Following Cardiac Catheterization Procedures: Contrast-Induced Encephalopathy Versus StrokeSotirios Dardas, Luciano Sposato, Diana Ayan, et al.
Molecular Cancer Therapeutics|August 24, 2012
A new nonestrogenic steroidal inhibitor of 17β-hydroxysteroid dehydrogenase type I blocks the estrogen-dependent breast cancer tumor growth induced by estroneDiana Ayan, René Maltais, Jenny Roy, et al.
Bioorganic & Medicinal Chemistry|October 11, 2014
Chemical synthesis, cytotoxicity, selectivity and bioavailability of 5α-androstane-3α,17β-diol derivativesDiana Ayan, René Maltais, Audrey Hospital, et al.
Plos One|December 15, 2015
The Aminosteroid Derivative RM-133 Shows In Vitro and In Vivo Antitumor Activity in Human Ovarian and Pancreatic CancersLucie Carolle Kenmogne, Diana Ayan, Jenny Roy, et al.
The Journal of Steroid Biochemistry and Molecular Biology|December 18, 2017
Pharmacokinetic profile of PBRM in rodents, a first selective covalent inhibitor of 17β-HSD1 for breast cancer and endometriosis treatmentsRené Maltais, Alexandre Trottier, Jenny Roy, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Bioorganic & Medicinal Chemistry Letters|July 26, 2011
Synthesis and preliminary evaluation of a modified estradiol-core bearing a fused γ-lactone as non-estrogenic inhibitor of 17β-hydroxysteroid dehydrogenase type 1Etienne Ouellet, Diana Ayan, Donald Poirier
Chemmedchem|June 8, 2012
Identification of a 17β-hydroxysteroid dehydrogenase type 10 steroidal inhibitor: a tool to investigate the role of type 10 in Alzheimer's disease and prostate cancerDiana Ayan, René Maltais, Donald Poirier
ACS Medicinal Chemistry Letters|September 20, 2011
Crucial Role of 3-Bromoethyl in Removing the Estrogenic Activity of 17β-HSD1 Inhibitor 16β-(m-Carbamoylbenzyl)estradiolRené Maltais, Diana Ayan, Donald Poirier
The Journal of Steroid Biochemistry and Molecular Biology|August 11, 2011
Impact of estradiol structural modifications (18-methyl and/or 17-hydroxy inversion of configuration) on the in vitro and in vivo estrogenic activityDiana Ayan, Jenny Roy, René Maltais, et al.
Journal of Medicinal Chemistry|May 8, 2019
Antisulfatase, Osteogenic, and Anticancer Activities of Steroid Sulfatase Inhibitor EO-33 in MiceDonald Poirier, Jenny Roy, René Maltais, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|April 30, 2026
Code Stroke Activation Following Cardiac Catheterization Procedures: Contrast-Induced Encephalopathy Versus StrokeSotirios Dardas, Luciano Sposato, Diana Ayan, et al.
Molecular Cancer Therapeutics|August 24, 2012
A new nonestrogenic steroidal inhibitor of 17β-hydroxysteroid dehydrogenase type I blocks the estrogen-dependent breast cancer tumor growth induced by estroneDiana Ayan, René Maltais, Jenny Roy, et al.
Bioorganic & Medicinal Chemistry|October 11, 2014
Chemical synthesis, cytotoxicity, selectivity and bioavailability of 5α-androstane-3α,17β-diol derivativesDiana Ayan, René Maltais, Audrey Hospital, et al.
Plos One|December 15, 2015
The Aminosteroid Derivative RM-133 Shows In Vitro and In Vivo Antitumor Activity in Human Ovarian and Pancreatic CancersLucie Carolle Kenmogne, Diana Ayan, Jenny Roy, et al.
The Journal of Steroid Biochemistry and Molecular Biology|December 18, 2017
Pharmacokinetic profile of PBRM in rodents, a first selective covalent inhibitor of 17β-HSD1 for breast cancer and endometriosis treatmentsRené Maltais, Alexandre Trottier, Jenny Roy, et al.
Pageof 3